Terminated PHASE2 INTERVENTIONAL 2-arm NCT02022358

Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?

A Randomised, Cross-over Phase II Study to Investigate the Efficacy and Safety of Glucarpidase for Routine Use After High Dose Methotrexate in Patients With Bone Sarcoma

Sponsor: Richard Scowcroft Foundation

Conditions Osteosarcoma Spindle Cell Sarcoma of Bone

Interventions Folinic Acid Glucarpidase Methotrexate

Updated 5 times since 2017 Last updated: Jun 3, 2015 Started: Jul 31, 2007 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Recruitment almost complete, has been slow and challenging

Other Osteosarcoma trials with similar outcome

Browse all Osteosarcoma trials

A PHASE2 clinical study on Osteosarcoma and Spindle Cell Sarcoma of Bone, this trial is terminated or withdrawn. The trial is conducted by Richard Scowcroft Foundation and has accumulated 5 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Richard Scowcroft Foundation
University College, London

Data source: University College, London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom